The Manufacturers Life Insurance Company Has $525.28 Million Holdings in Abbott Laboratories $ABT

The Manufacturers Life Insurance Company lifted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 67.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,116,192 shares of the healthcare product maker’s stock after purchasing an additional 2,059,108 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Abbott Laboratories were worth $525,279,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. J. Stern & Co. LLP grew its position in Abbott Laboratories by 12,439.6% during the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after buying an additional 39,005,451 shares in the last quarter. Norges Bank acquired a new position in Abbott Laboratories in the 4th quarter valued at $2,938,892,000. Arrowstreet Capital Limited Partnership lifted its position in shares of Abbott Laboratories by 217.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 5,522,222 shares of the healthcare product maker’s stock valued at $566,967,000 after acquiring an additional 3,780,402 shares during the period. Assenagon Asset Management S.A. grew its holdings in shares of Abbott Laboratories by 303.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker’s stock worth $454,784,000 after purchasing an additional 3,330,368 shares in the last quarter. Finally, Ninety One UK Ltd acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth $336,815,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Trading Up 1.5%

Shares of ABT stock opened at $104.61 on Tuesday. The firm has a market capitalization of $182.20 billion, a P/E ratio of 33.85, a P/E/G ratio of 2.00 and a beta of 0.61. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The stock’s fifty day simple moving average is $91.95 and its 200 day simple moving average is $100.99.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The firm had revenue of $12.51 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The business’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same period last year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Wall Street Analysts Forecast Growth

ABT has been the subject of a number of analyst reports. Piper Sandler reaffirmed an “overweight” rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. UBS Group decreased their target price on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Jefferies Financial Group dropped their target price on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Mizuho reduced their price target on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. Finally, BTIG Research lifted their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $118.61.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.